Uncategorized
Eyes with macular retinoschisis respond poorly to early ranibizumab injections
Myopic eyes with macular retinoschisis and choroidal neovascularization responded poorly to intravitreal ranibizumab after 3 months of treatment, according to a study from the University of Bern.More Lucentis (ranibizumab, Genentech) injections were needed in eyes with macular retinoschisis than eyes without macular retinoschisis to gain comparable best corrected visual acuity by 12 months, the study authors said.